,i  #aafth ,,congress  #b;d ,session    
,h4 ,r4 #fbfa  ,,in ,,the ,,house ,,of  
,,representatives  ,march #ab1 #bjbj,mr4
 ,ruiz introduced the following bill2   
which was referred to the ,committee on 
,natural ,resources1 and in addition to 
the ,committee on ,energy and ,commerce1
 for a period to be subsequently        
determined by the ,speaker1 in each case
 for consideration of such provisions as
 fall within the jurisdiction of the    
committee concerned  ,a ,,bill  ,to     
provide for coverage of testing for     
,,covid-#ai at no cost sharing for      
,indians receiving health services      
through the ,indian ,health ,service1   
and for other purposes4  #a4 ,coverage  
of testing for ,,covid-#ai at no cost   
sharing for ,indians receiving health   
services through ,indian ,health        
,service ,the ,secretary of ,health and 
,human ,services shall cover1 without   
the imposition of any cost sharing      
requirements1 the cost of providing the 
following items and services furnished  

during any portion of the emergency     
period defined in paragraph 7#a77;,b7 of
 section #aace7;g7 of the ,social       
,security ,act 7#db ,u4,s4,c4           
#acbj;b-#e7;g77 beginning on or after   
the date of the enactment of this ,act  
to ,indians 7as defined in section #d of
 the ,indian ,health ,care ,improvement 
,act 7#be ,u4,s4,c4 #afjc77 receiving   
health services through the ,indian     
,health ,service1 regardless of whether 
such items or services have been        
authorized under the contract health    
services system funded by the ,indian   
,health ,service or are covered as a    
health service of the ,indian ,health   
,service3 7#a7 ,in vitro diagnostic     
products 7as defined in section         
#hji4c7;a7 of title #ba1 ,code of       
,federal ,regulations7 for the detection
 of ,,sars-,co,v-#b or the diagnosis of 
the virus that causes ,,covid-#ai that  
are approved1 cleared1 or authorized    
under section #eaj7k71 #eac1 #eae1 or   
#efd of the ,federal ,food1 ,drug1 and  

,cosmetic ,act1 and the administration  
of such in vitro diagnostic products4   
7#b7 ,health care provider office       
visits1 urgent care center visits1 and  
emergency room visits relating to       
testing for ,,covid-#ai4